FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565641385> ?p ?o ?g. }

• W2565641385 abstract "Abstract Background: Thalidomide (T) and bortezomib (B) in combination with melphalan-prednisone (MP) were both shown to be superior to treatment with MP. However, head-to-head comparison of these regimens is lacking. When direct comparison is not available, indirect meta-analysis of randomized controlled trials (RCTs) can be performed. Such an analysis preserves the original randomization and therefore is considered to be more reliable than comparison based on non-RCT data. Methods: Previously described methods for adjusted indirect comparisons developed by Bucher et al and Glenny et al were used. We created the following chain of inference: we first pooled RCTs that compared MPT with MP, and BMP vs. MP. We then compared the pooled estimate to obtain the unbiased estimate in treatment differences between BMP vs. MPT. Results: 4 RCTs compared MPT vs. MP and 1 BMP vs. MP. Data from RCT by Waage et.al. were not available. The results for all comparisons are summarized in the table. Meta-analysis of 3 RCTs comparing MPT vs. MP showed no difference in overall survival (OS), and treatment-related mortality (TRM). However, event-free survival (EFS), partial response (PR), complete response (CR) and very good partial response (VGPR) were significantly better with MPT, but at the risk of significant grade III-IV adverse events (AE), and deep-vein thrombosis (DVT). OS, EFS, CR and VGPR was significantly better with BMP vs MP in 1 RCT, but at significant risk for grade III-IV AE. There was no difference between BMP and MP in terms of TRM, DVT, and PR. Comparison of BMP versus MPT showed no difference in OS, EFS, TRM, DVT, and PR. However BMP is associated with significantly less grade III-IV AE and better CR. Conclusion: There was no difference in OS, EFS, or TRM between BMP and MPT. However, treatment with BMP results in improved complete response, while grade III-IV AE were more common in MPT arm. The lack of statistical difference is likely due to insufficient power (absence of evidence) rather than true differences of no effect (evidence of absence). Since the power of this indirect meta-analysis was low, direct head-to-head comparison between these competing regimens is warranted. Table. Outcome Comparisons MPT versus MP (3 RCT; N= 852) Conclusion BMP versus MP (1 RCT; N=682) Conclusion BMP versus MPT Conclusion OS HR=0.747 (95%CI 0.534, 0.046); p=0.089 No difference HR=0.607 (95%CI 0.425, 0.866); p=0.006 BMP better HR=0.812 (95%CI 0.498, 1.325); p=0.405 No difference EFS HR=0.569 (95%CI 0.484, 0.668); p=0 MPT better HR=0.483 (95%CI 0.37, 0.63); p=0 BMP better HR=0.85 (95%CI 0.623, 1.159); p=0.304 No difference TRM Risk ratio (RR)=0.976 (95%CI 0.469, 2.031); p=0.949 No difference RR=0.566 (95%CI 0.167, 1.917); p=0.361 No difference RR=0.58 (95%CI 0.14, 2.405); p=0.453 No difference DVT RR=3.586 (95%CI 2.021, 6.632); p=0.00 MP better RR=0.991 (95%CI 0.243, 4.041); p=0.99 No difference RR=0.276 (95%CI 0.61, 1.261); p=0.0971 No difference Grade III-IV AE RR=4.257 (95%CI 3.402, 5.327); p=0.0 MP better RR=1.512 (95%CI 1.255, 1.814); p=0.0 MP better RR=0.355 95%CI 0.265, 0.474; p=0.00 BMP better CR RR=0.911 (95%CI 0.875, 0.948); p=0.00 MPT better RR=0.728 (95%CI 0.676, 0.783); p=0 BMP better RR=0.799 (95%CI 0.735, 0.869); p=0.00 BMP better VGPR RR=0.778 (95%CI 0.720, 0.840); p=0.005 MPT better RR=0.947 (95%CI 0.907, .990); p=0.016 BMP better RR=1.219 (95%CI 1.115, 1.331); p=0.00 MPT better PR RR=0.885 (95%CI 0.794, 0.986); p=0.027 MPT better RR=0.914 (95%CI 0.821, 1.018); p=0.101 No difference RR=1.033 (95%CI 0.887, 1.203); p=0.675 No difference" @default.
• W2565641385 created "2017-01-06" @default.
• W2565641385 creator A5021167699 @default.
• W2565641385 creator A5076100445 @default.
• W2565641385 creator A5091393669 @default.
• W2565641385 date "2008-11-16" @default.
• W2565641385 modified "2023-10-18" @default.
• W2565641385 title "Thalidomide Versus Bortezomib-Based Regimens for Relapsed Myeloma: Meta-Analysis and Indirect Meta-Analysis" @default.
• W2565641385 doi "https://doi.org/10.1182/blood.v112.11.2362.2362" @default.
• W2565641385 hasPublicationYear "2008" @default.
• W2565641385 type Work @default.
• W2565641385 sameAs 2565641385 @default.
• W2565641385 citedByCount "0" @default.
• W2565641385 crossrefType "journal-article" @default.
• W2565641385 hasAuthorship W2565641385A5021167699 @default.
• W2565641385 hasAuthorship W2565641385A5076100445 @default.
• W2565641385 hasAuthorship W2565641385A5091393669 @default.
• W2565641385 hasConcept C126322002 @default.
• W2565641385 hasConcept C141071460 @default.
• W2565641385 hasConcept C143998085 @default.
• W2565641385 hasConcept C168563851 @default.
• W2565641385 hasConcept C197934379 @default.
• W2565641385 hasConcept C204243189 @default.
• W2565641385 hasConcept C2776364478 @default.
• W2565641385 hasConcept C2777478702 @default.
• W2565641385 hasConcept C2778684742 @default.
• W2565641385 hasConcept C2779609412 @default.
• W2565641385 hasConcept C44249647 @default.
• W2565641385 hasConcept C71924100 @default.
• W2565641385 hasConcept C90924648 @default.
• W2565641385 hasConcept C95190672 @default.
• W2565641385 hasConceptScore W2565641385C126322002 @default.
• W2565641385 hasConceptScore W2565641385C141071460 @default.
• W2565641385 hasConceptScore W2565641385C143998085 @default.
• W2565641385 hasConceptScore W2565641385C168563851 @default.
• W2565641385 hasConceptScore W2565641385C197934379 @default.
• W2565641385 hasConceptScore W2565641385C204243189 @default.
• W2565641385 hasConceptScore W2565641385C2776364478 @default.
• W2565641385 hasConceptScore W2565641385C2777478702 @default.
• W2565641385 hasConceptScore W2565641385C2778684742 @default.
• W2565641385 hasConceptScore W2565641385C2779609412 @default.
• W2565641385 hasConceptScore W2565641385C44249647 @default.
• W2565641385 hasConceptScore W2565641385C71924100 @default.
• W2565641385 hasConceptScore W2565641385C90924648 @default.
• W2565641385 hasConceptScore W2565641385C95190672 @default.
• W2565641385 hasLocation W25656413851 @default.
• W2565641385 hasOpenAccess W2565641385 @default.
• W2565641385 hasPrimaryLocation W25656413851 @default.
• W2565641385 hasRelatedWork W2127723690 @default.
• W2565641385 hasRelatedWork W2240448657 @default.
• W2565641385 hasRelatedWork W2334803727 @default.
• W2565641385 hasRelatedWork W2349136538 @default.
• W2565641385 hasRelatedWork W2363397485 @default.
• W2565641385 hasRelatedWork W2385652935 @default.
• W2565641385 hasRelatedWork W2461782422 @default.
• W2565641385 hasRelatedWork W2551535949 @default.
• W2565641385 hasRelatedWork W2726692283 @default.
• W2565641385 hasRelatedWork W2784121544 @default.
• W2565641385 hasRelatedWork W2808295405 @default.
• W2565641385 hasRelatedWork W2914994266 @default.
• W2565641385 hasRelatedWork W2923752905 @default.
• W2565641385 hasRelatedWork W2985909340 @default.
• W2565641385 hasRelatedWork W3005887226 @default.
• W2565641385 hasRelatedWork W3031341881 @default.
• W2565641385 hasRelatedWork W3082012811 @default.
• W2565641385 hasRelatedWork W3197123363 @default.
• W2565641385 hasRelatedWork W2400449691 @default.
• W2565641385 hasRelatedWork W2442295132 @default.
• W2565641385 isParatext "false" @default.
• W2565641385 isRetracted "false" @default.
• W2565641385 magId "2565641385" @default.
• W2565641385 workType "article" @default.